U.S. Drug Industry Faces Potential 200% Tariff Impact
Originally Published 6 months ago — by STAT
Merck is acquiring Verona Pharma for $10 billion to strengthen its lung-disease portfolio, while U.S. political developments threaten to impact drugmakers through potential high tariffs and Medicaid funding cuts, notably affecting companies like Gilead and Vertex. Additionally, new clinical trials are underway for gene therapies targeting muscle-wasting diseases, and Gilead has committed to providing its HIV prevention drug to millions in low-income countries at no profit.